A Case of Non-Small Cell Lung Cancer with Mutually Exclusive EGFR and KRAS Mutations
Open Access
- 20 January 2025
- journal article
- case report
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (1) , 66
Abstract
Historically, EGFR and KRAS mutations were believed to be mutually exclusive. However, over the past few years, there have been emerging case reports showing the co-existence of both mutations in a single case. The majority of these co-occurring alterations were detected in samples collected from patients with resistance to tyrosine kinase inhibitor (TKI) treatment, indicating a potential functional role in driving resistance to therapy. These co-occurring tumor genomic alterations are not necessarily mutually exclusive, and evidence suggests that multiple clonal and sub-clonal cancer cell populations can co-exist and contribute to EGFR TKI resistance. We have reported such a case of concomitant EGFR and KRAS mutation in a 64-year-old female. This case highlights the importance of continuous molecular testing in managing NSCLC, especially in cases with rare mutation profiles. The emergence of new mutations during treatment can significantly impact the course of therapy and patient outcomes. In this case, the detection of both EGFR and KRAS mutations guided the selection of an appropriate targeted therapeutic strategy, including the use of Amivantamab.Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung CancerJCO Precision Oncology, 2024
- Novel therapeutic strategies for rare mutations in non-small cell lung cancerScientific Reports, 2024
- Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistanceJournal of Hematology & Oncology, 2022
- Classification of KRAS -Activating Mutations and the Implications for Therapeutic InterventionCancer Discovery, 2022
- Cancer statistics in China and United States, 2022: profiles, trends, and determinantsChinese Medical Journal, 2022
- P76.33 Concurrent EGFR and KRAS Mutations in Lung Adenocarcinoma: A Single Institution Case SeriesJournal of Thoracic Oncology, 2021
- Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAFCancer Medicine, 2019
- EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patientLung Cancer, 2016
- Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancerBritish Journal of Cancer, 2014
- Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung AdenocarcinomaJournal of Thoracic Oncology, 2008